All Articles

THIS MONTH’S FEATURED ARTICLE

GBCAs: what is known, what is unknown?

Jared Allen, MD, PhD

In light of the FDA safety bulletin updated Jan. 1, 2018 about gadolinium contrast agents (GBCAs), and the recent increased awareness of the issue owing to a lawsuit filed by martial arts star, Chuck Norris, there have been heightened concerns and increased confusion around GBCAs used with MRIs. The FDA is now requiring patient information be shared with those receiving contrast. Read More.